A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity
oleh: Miriam Y. Kim, Reyka Jayasinghe, Jessica M. Devenport, Julie K. Ritchey, Michael P. Rettig, Julie O’Neal, Karl W. Staser, Krista M. Kennerly, Alun J. Carter, Feng Gao, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-06-01 |
Deskripsi
Chimeric antigen receptor T cells represent a breakthrough treatment in hematologic malignancies, but insufficient level of cytotoxicity and persistence of T cells might compromise success. Authors show here that a recombinant long acting form of interleukin-7 enhances proliferation, persistence and cytotoxicity of the engineered T cells, resulting in long term disease remission.